InsidersTradesSigma
申报总数
公司
▲ 买入（3 笔）
▼ 卖出（0 笔）
内部人交易记录
董事已披露买入
3
已披露卖出
0
T+90 胜率
0%
T+90 平均收益
-11.6%
基于 2 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Explore the complete record of transactions filed by Mathers Edward T, 董事. Insider active across 9 companies, notably Monte Rosa Therapeutics, Inc.. In total, 17 filings have been recorded. Split: 3 buys · 0 sell. Total volume traded: €3.8m. History available since 11 April 2022. The latest transaction was disclosed on 12 March 2026 (J). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Mathers Edward T
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报17 总计
4,199 股0Common StockSEC:0001193125-26-108351:0
207,100 股@ US$11.1167.8% 占其流量Common StockSEC:0001193125-26-104715:0
标准退出：2026年6月8日 (T+90)
4,198 股0Common StockSEC:0001193125-26-091684:0
1,619,240 股Common StockSEC:0001193125-26-046664:0
3,911 股0Class A Common StockSEC:0001193125-26-000942:0
189,195 股@ US$0.01100.0% 占其流量Common StockSEC:0001193125-25-232136:0
4,125 股0Class A Common StockSEC:0001193125-25-228402:0
4,694 股0Class A Common StockSEC:0000950170-25-093063:0
4,000 股Common StockSEC:0000950170-25-089052:0
2,580 股0Class A Common StockSEC:0000950170-25-049473:0
1,023,103 股Common StockSEC:0000950170-24-107558:0
3,000 股Common StockSEC:0000950170-24-077346:0
17,857 股@ US$56.00100.0% 占其流量Common StockSEC:0000950170-24-047681:0
标准退出：2024年7月21日 (T+90)
333,333 股@ US$3.00100.0% 占其流量Common StockSEC:0001209191-23-042802:0
标准退出：2023年10月15日 (T+90)
5,771 股0Common StockSEC:0001209191-23-016175:0
948,948 股@ US$1.90100.0% 占其流量Common StockSEC:0001209191-22-024323:0
2,715,968 股Common StockSEC:0001209191-21-044044:0
17 条申报中的 17 条
About Mathers Edward T
Mathers Edward T is Administrateur and has filed 17 filings in total. In the 17 most recent filings held, cumulative purchases amount to EUR 3809047, sales to EUR 0, and the period runs from 2021-06-30 to 2026-03-16. Among the main filings are transactions involving Korro Bio, Inc., NeueHealth, Inc., Rhythm Pharmaceuticals, INC., Trevi Therapeutics, Inc. and Savara Inc.
